Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  trametinib
Find trials that include:  Any drugs shown
Results 1-25 of 45 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6134, NCI-2014-01747, NCT02224781
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 120
Trial IDs: CPDR001F2301, NCI-2017-00814, 2016-002794-35, NCT02967692
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9525, NCI-2014-00461, 13-505, NCT02079740
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20120238, NCI-2014-01974, NCT02110355
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-022, NCI-2014-02160, 2015-000681-55, NCT02130466
Dabrafenib, Trametinib and Hydroxychloroquine in Treating Patients with Stage IV Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 02614, NCI-2015-00364, 819986, NCT02257424
Dabrafenib, Trametinib, and Navitoclax in Treating Patients with BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9466, NCI-2013-02103, 13-424, NCT01970956, NCT01989585
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTMT212X2106, NCI-2016-01156, 2015-005019-34, NCT02703571
Trametinib and Erlotinib Hydrochloride in Treating Patients with Stage IV or Recurrent Lung Cancer with EGFR Activating Mutation
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 15-098, NCI-2017-00542, NCT03076164
Ceritinib and Trametinib in Treating Patients with ALK Positive Stage IIIB-IV Non-small Cell Lung Cancer
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 166512, NCI-2017-01318, 16-20614, NCT03087448
GSK1120212 Rollover Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9149, NCI-2013-01588, 130105, MPACT, P121047, NCT01827384
Trametinib and GSK2141795 in Treating Patients With Stage III-IV Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC #13855, NCI-2013-01849, 13855, NCT01941927
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Metastatic, Persistent, or Recurrent Cervical Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-334, NCI-2013-02357, NCT01958112
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116521, NCI-2014-01364, NCT01978236
Effects of Endocrine Therapy with or without Trametinib or Dasatinib in Patients with Localized, Untreated Prostate Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-000714, NCI-2015-01448, EMT13001, NCI-2014-02414, NCT01990196
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Trametinib in Increasing Tumoral Iodine Incorporation in Patients with Recurrent or Metastatic Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9446, NCI-2014-01106, 13-157, NCT02152995
Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1320, NCI-2014-01470, NCT02199730, S1221, NCT02196181
Dabrafenib and Trametinib before and after Surgery in Treating Patients with Stage IIIB-C Melanoma with BRAF V600 Mutation
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0409, NCI-2014-01969, NCT02231775
Trametinib in Treating Patients with Advanced Melanoma with BRAF Non-V600 Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC MEL 1457, NCI-2014-02185, GSK1120212, MEL1457, NCT02296112
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Trametinib and Docetaxel in Treating Patients with Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1507, NCI-2015-02250, NCT02642042
Dabrafenib and Trametinib in Treating Patients with Erdheim Chester Disease and BRAF Mutation
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9598, NCI-2014-02197, 15-HG-0006, NCT02281734, T-HG-0112, NCT02281760
Start Over